yingweiwo

JNJ4796

Alias: JNJ-4796; JNJ4796; JNJ 4796
Cat No.:V4512 Purity: ≥98%
JNJ4796 is a novel, potent and oral bioactive fusion inhibitor of influenza virus, which neutralizes influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion.
JNJ4796
JNJ4796 Chemical Structure CAS No.: 2241664-16-2
Product category: New7
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg
10mg
50mg
100mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description
JNJ4796 is a novel, potent and oral bioactive fusion inhibitor of influenza virus, which neutralizes influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 was identified through structural knowledge of the interactions and mechanism of anti-stem bnAb CR6261. It mimics the functionality of the broadly neutralizing antibodies (bnAbs). Recent characterization of broadly neutralizing antibodies (bnAbs) against influenza virus identified the conserved hemagglutinin (HA) stem as a target for development of universal vaccines and therapeutics. Although several stem bnAbs are being evaluated in clinical trials, antibodies are generally unsuited for oral delivery.
JNJ4796 is a novel, potent, and oral bioactive fusion inhibitor of influenza virus. It neutralizes influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. It is an oral active influenza virus fusion inhibitor. Influenza virus hemagglutinin is a surface glycoprotein that mediates viral entry by fusing the viral envelope with the host cell membrane.
Biological Activity I Assay Protocols (From Reference)
Targets
Influenza virus hemagglutinin (HA).
ln Vitro
Similar to bnAb CR6261, JNJ4796 was demonstrated to work by blocking the pH-sensitive conformational changes of HA, which in turn caused the viral and endosomal membranes to fuse and release the viral DNA into the host cell [1].
JNJ4796 is a potent inhibitor of influenza virus that neutralizes influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. The compound's in vitro activity is characterized by its ability to bind to the HA protein and block the conformational changes required for membrane fusion, thereby preventing viral entry and infection. Specific EC50 values are not detailed in the available literature.
ln Vivo
Mice were protected against lethal challenge with 25 times the median lethal dose (LD50) of the H1N1 A/Puerto Rico/8/1934 virus by oral treatment of JNJ4796. In contrast to less than 50% survival with the less potent chemical JNJ8897, twice-daily dosages of JNJ4796 at 50 and 10 mg/kg, started the day before the challenge and continued for 7 days, resulted in 100% survival at day 21. 1]. After a sublethal viral challenge (LD90), oral dosages of JNJ4796 demonstrated dose-dependent effectiveness; at doses of 15 and 5 mg/kg twice daily, 100% survival was attained [1].
JNJ4796 is an oral active fusion inhibitor of influenza virus. Specific in vivo activity data is not detailed in the available literature. Based on its mechanism of action as an HA-mediated fusion inhibitor, it is expected to demonstrate antiviral efficacy in animal models of influenza infection, such as mice or ferrets. The compound's ability to reduce viral load, improve survival, and ameliorate disease symptoms would be assessed.
Enzyme Assay
In vitro antiviral assays using influenza virus-infected cells to evaluate the compound's ability to inhibit viral replication. Cells are infected with influenza virus and treated with varying concentrations of the compound, and viral titers or viral RNA levels are measured to determine the EC50 values. Fusion inhibition assays are performed to evaluate the compound's ability to block HA-mediated membrane fusion.
Cell Assay
Cell-based assays evaluating influenza virus inhibition. Cells are infected with influenza virus and treated with the compound, and the cytopathic effect is measured. Viral replication is assessed by measuring the levels of viral proteins or viral RNA by ELISA or qRT-PCR. The compound's effects on cell viability and cytotoxicity are also assessed.
Animal Protocol
Animal/Disease Models: Female BALB/cAnNCrl mice were infected intranasally with 2 × 25 μL of 25 × LD50 or 1 × LD90 of H1N1 A/Puerto Rico/8/34[1 ]
Doses: 50 and 10 mg/kg. Directions: Take orally twice (two times) daily for 7 days.
Experimental Results: Day 21 survival was 100% compared to the less potent compound JNJ8897.
In vivo efficacy is evaluated in animal models of influenza infection, such as mice or ferrets. The compound is administered orally, and endpoints include viral load in the lungs, survival, weight loss, and clinical signs of infection. The compound's ability to reduce viral replication and improve disease outcome is assessed.
References

[1]. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019 Mar 8;363(6431).

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C28H27N9O3
Molecular Weight
537.572484254837
Exact Mass
537.223
CAS #
2241664-16-2
PubChem CID
135302421
Appearance
White to light yellow solid powder
LogP
2.6
tPSA
135
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
9
Rotatable Bond Count
6
Heavy Atom Count
40
Complexity
881
Defined Atom Stereocenter Count
1
SMILES
O=C(C1C=C(C2=NC3C=C(C=CC=3O2)NC(C)=O)C=CN=1)N1CCN([C@@H](C2N=NN(C)N=2)C2C=CC=CC=2)CC1
InChi Key
VMAAUIZLAZYALS-RUZDIDTESA-N
InChi Code
InChI=1S/C28H27N9O3/c1-18(38)30-21-8-9-24-22(17-21)31-27(40-24)20-10-11-29-23(16-20)28(39)37-14-12-36(13-15-37)25(19-6-4-3-5-7-19)26-32-34-35(2)33-26/h3-11,16-17,25H,12-15H2,1-2H3,(H,30,38)/t25-/m1/s1
Chemical Name
N-[2-[2-[4-[(R)-(2-methyltetrazol-5-yl)-phenylmethyl]piperazine-1-carbonyl]pyridin-4-yl]-1,3-benzoxazol-5-yl]acetamide
Synonyms
JNJ-4796; JNJ4796; JNJ 4796
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO : ~100 mg/mL (~186.02 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8602 mL 9.3011 mL 18.6022 mL
5 mM 0.3720 mL 1.8602 mL 3.7204 mL
10 mM 0.1860 mL 0.9301 mL 1.8602 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us